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OBJECTIVES: Complicated skin and soft tissue infections
(cSSTIs) are a common cause of morbidity at community and
hospital levels. The present study aims at evaluating the costs and
outcomes of antibiotic therapy for the treatment of cSSTI in Italy.
METHODS: The study was designed as retrospective, multi-
centre, incidence-based and observational. The hospital perspec-
tive was considered. Seven hospitals were selected across the
country and each hospital was asked to retrospectively recruit
patients from January 2003 to August 2006. Hospitals were
identiﬁed amongst those highly specialized in the treatment of
infectious diseases and diabetic foot. The target population con-
sisted of adult patients eligible to receive antibiotic therapy for
cSSTI that was due at least in part to gram-positive organism and
that required hospitalization and parenteral antimicrobial
therapy for at least 96 hours. Consistently with the study per-
spective, direct hospital costs have been identiﬁed and measured
through a micro-costing approach. Clinical variables and cost
data were drawn from patients’ medical records and registered
on Case Report Forms. RESULTS: A cohort of 307 patients was
enrolled. Failure of initial antibiotic therapy resulted in 23% of
patients. Average treatment with antibiotics lasted for 14.3 days
and full cost of admission totalled Euro 6404. The right choice of
ﬁrst line antibiotics could save up to 3000 Euro per patient in
case of “failure” avoided, of which 889 Euro were avoidable
costs, that is they could actually be saved in the very short-run.
These could be ultimately increased by Euro 92 for each hospital
day avoided because of faster antibiotic action. CONCLUSION:
Hospital resources could be freed and patients’ outcomes
improved if 1) the right antibiotic is immediately selected at
patient’s admission, and 2) the quickest antibiotic is chosen in
eradicating the infection.
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OBJECTIVES: Skin and soft tissue infection (SSTI) is a hetero-
geneous disease caused predominantly by Staphylococcus aureus
and Gram-negative pathogens. The choice of anti-infective
therapy varies depending on patterns of pathogen resistance,
including prevalence of methicillin-resistant Staphylococcus
aureus (MRSA). The objective of this study is to understand
treatment patterns and outcomes in patients with SSTI in
Belgium. METHODS: Data obtained from January–June 2004
Minimum Basic Data Set from 37 hospitals in Belgium, repre-
senting approximately 27% of total hospital beds, were used to
identify patients hospitalized with SSTI using ICD-9 diagnostic
codes and use of at least one intravenous antibiotic. Prescription
claims were used to classify AI use into categories based on
spectrum of activities, and were further divided into three cat-
egories: patients who received a broad spectrum agent and no
anti-MRSA coverage (A), patients received a broad spectrum and
later switch to (or add) anti-MRSA agent (B), and patients who
received anti-MRSA and no broad spectrum agents (C). Anti-
MRSA coverage classiﬁcation was based on use of glycopeptides
(vancomycin and teicoplanin). Costs are expressed in 2004 Euros
RESULTS: A total of 607 patients were included in this study.
The overall proportion of patients treated with anti-MRSA
(groups B + C) was 16%. The number of co-diagnoses for groups
A, B, and C were 13.5, 20.5, and 15.5, respectively. Mean
(median) length of stay (LOS) was 29.4 (19.0), 42.2 (34.0) and
32.9 (24.5) for groups A, B, and C, respectively. Mortality rate
was 13.3%, 30.2%, and 18.5% and median total costs were
8,423.00, 19,071.99 and 11,057.61 Euros, for groups A, B, and
C, respectively. CONCLUSION: Patients who develop SSTI with
MRSA are very costly. Early identiﬁcation of patients at risk of
SSTI involving MRSA and timely administration of appropriate
AI therapy has signiﬁcant implications on reducing costs and
improving outcomes.
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OBJECTIVES: The purpose of this study was to evaluate
outcomes and costs of Ventilator-Associated Pneumonia (VAP)
and Nosocomial Pneumonia (NP) caused by Pseudomonas
or Methicillin-Resistant Staphylococcus Aureus (MRSA).
METHODS: Data analyses were performed using the January–
June 2004 Minimum Basic Dataset that included data from 37
Belgian hospitals. NP patients were identiﬁed using an ICD-
9-CM code of bacterial pneumonia (481.xx-486.xx) and at least
one IV antibiotic administration during their hospital stay.
Patients receiving mechanical ventilation were identiﬁed using
the ICD-9-CM procedure code 96.7 and its sub-codes. VAP and
NP patients were further classiﬁed based on the infecting patho-
gen: Pseudomonas, MRSA, or Other. RESULTS: A total of 287
VAP patients and 757 NP patients and were included in the
analyses. VAP patients were sicker and had worse outcomes
(hospital length of stay or LOS, mortality, and total hospital
costs) than NP patients. VAP/NP patients with Pseudomonas or
MRSA were older and sicker compared to VAP/NP in the Other
group. LOS (days) for the VAP patients in the Pseudomonas (37)
and MRSA (31) groups were higher than in the Other (29)
group. For NP, the median LOS for the Pseudomonas (29) and
MRSA (31) were higher than in Other (21). Hospital costs
for the Pseudomonas group (Euros) were VAP = €31,602,
NP = €13,832; for the MRSA group were VAP = €17,767; NP =
€17,208; and Other group were VAP = €18,965, NP = €10,687.
Mortality rates were higher in the Pseudomonas group
(VAP = 54%, NP = 27%) compared to the Other group (VAP =
36%, NP = 16%); the numbers for MRSA were VAP = 27%,
NP = 36%. The number of patients in the VAP-MRSA group
(n = 11) was too small to make any meaningful conclusions.
CONCLUSION: Overall, VAP patients had signiﬁcantly worse
outcomes and higher costs compared to NP patients.
Pseudomonas-infected VAP/NP patients and MRSA–infected NP
patients had worse outcomes and higher costs compared to
VAP/NP patients infected with other pathogens.
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